Media center
Press release
Owkin announces first patient dosed in Phase 1 Clinical Trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for patients with solid tumors
January 30, 2025
Press release
Owkin announces first patient dosed in Phase 1 Clinical Trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for patients with solid tumors
January 30, 2025
Explore
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
In the media
Wall Street Journal features CEO Thomas Clozel
February 10, 2025
Wall Street Journal features CEO Thomas Clozel
February 10, 2025
WSJ
In the media
Les Echos covers Owkin’s role in AI in healthcare for the AI Action Summit
February 9, 2025
Les Echos covers Owkin’s role in AI in healthcare for the AI Action Summit
February 9, 2025
Les Echos
In the media
Owkin’s CEO, Thomas Clozel named in Le Figaro’s top 7 french leaders in AI
February 6, 2025
Owkin’s CEO, Thomas Clozel named in Le Figaro’s top 7 french leaders in AI
February 6, 2025
Le Figaro
In the media
France 24 covers Owkin’s Glioblastoma AI Hackathon
February 4, 2025
France 24 covers Owkin’s Glioblastoma AI Hackathon
February 4, 2025
France 24
In the media
STAT interviews Owkin SVP Andrew Pierce about OKN4395
January 30, 2025
STAT interviews Owkin SVP Andrew Pierce about OKN4395
January 30, 2025
STAT
Press release
Owkin announces first patient dosed in Phase 1 Clinical Trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for patients with solid tumors
January 30, 2025
Owkin announces first patient dosed in Phase 1 Clinical Trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for patients with solid tumors
January 30, 2025
Press release
Owkin announces Owkin K1.0 Turbigo, a cutting-edge operating system to create the first AGI for biology, at JP Morgan Healthcare Conference
January 13, 2025
Owkin announces Owkin K1.0 Turbigo, a cutting-edge operating system to create the first AGI for biology, at JP Morgan Healthcare Conference
January 13, 2025
Press release
Absci and Owkin synergize leading TechBio platforms to advance generative AI drug discovery
January 10, 2025
Absci and Owkin synergize leading TechBio platforms to advance generative AI drug discovery
January 10, 2025
Press release
Owkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcare
December 12, 2024
Owkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcare
December 12, 2024
Press release
Owkin and Proscia expand access to AI pre-screening for colorectal cancer patients
November 19, 2024
Owkin and Proscia expand access to AI pre-screening for colorectal cancer patients
November 19, 2024
Press release
Owkin announces MSIntuit® CRC v2, a next-generation AI diagnostic aimed at transforming the detection and treatment of colorectal cancer
October 29, 2024
Owkin announces MSIntuit® CRC v2, a next-generation AI diagnostic aimed at transforming the detection and treatment of colorectal cancer
October 29, 2024